Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma.
Chiffelle J, Barras D, Pétremand R, Orcurto A, Bobisse S, Arnaud M, Auger A, Rodrigo BN, Ghisoni E, Sauvage C, Saugy D, Michel A, Murgues B, Fahr N, Imbimbo M, Ochoa de Olza M, Latifyan S, Crespo I, Benedetti F, Genolet R, Queiroz L, Schmidt J, Homicsko K, Zimmermann S, Michielin O, Bassani-Sternberg M, Kandalaft LE, Dafni U, Corria-Osorio J, Trueb L, Dangaj Laniti D, Harari A, Coukos G. Chiffelle J, et al. Among authors: kandalaft le. Immunity. 2024 Oct 8;57(10):2466-2482.e12. doi: 10.1016/j.immuni.2024.08.014. Epub 2024 Sep 13. Immunity. 2024. PMID: 39276771
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.
Genolet R, Bobisse S, Chiffelle J, Arnaud M, Petremand R, Queiroz L, Michel A, Reichenbach P, Cesbron J, Auger A, Baumgaertner P, Guillaume P, Schmidt J, Irving M, Kandalaft LE, Speiser DE, Coukos G, Harari A. Genolet R, et al. Among authors: kandalaft le. Cell Rep Methods. 2023 Apr 24;3(4):100459. doi: 10.1016/j.crmeth.2023.100459. eCollection 2023 Apr 24. Cell Rep Methods. 2023. PMID: 37159666 Free PMC article.
Personalized approaches to active immunotherapy in cancer.
Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE. Ophir E, et al. Among authors: kandalaft le. Biochim Biophys Acta. 2016 Jan;1865(1):72-82. doi: 10.1016/j.bbcan.2015.07.004. Epub 2015 Aug 1. Biochim Biophys Acta. 2016. PMID: 26241169 Review.
Whole Tumor Antigen Vaccines: Where Are We?
Chiang CL, Coukos G, Kandalaft LE. Chiang CL, et al. Among authors: kandalaft le. Vaccines (Basel). 2015 Apr 23;3(2):344-72. doi: 10.3390/vaccines3020344. Vaccines (Basel). 2015. PMID: 26343191 Free PMC article. Review.
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A. Bobisse S, et al. Among authors: le bitoux ma, kandalaft le. Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0. Nat Commun. 2018. PMID: 29545564 Free PMC article.
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E, Fahr N, Desbuisson M, Grimm A, Zhang H, Chong C, Dagher J, Chee S, Tsianou T, Dorier J, Stevenson BJ, Iseli C, Ronet C, Bobisse S, Genolet R, Walton J, Bassani-Sternberg M, Kandalaft LE, Ren B, McNeish I, Swisher E, Harari A, Delorenzi M, Ciriello G, Irving M, Rusakiewicz S, Foukas PG, Martinon F, Dangaj Laniti D, Coukos G. Bruand M, et al. Among authors: kandalaft le. Cell Rep. 2021 Jul 20;36(3):109412. doi: 10.1016/j.celrep.2021.109412. Cell Rep. 2021. PMID: 34289354 Free PMC article.
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, Grimm AJ, Casado J, Genolet R, Benedetti F, Wicky A, Ioannidou K, Castro W, Neal C, Moriot A, Renaud-Tissot S, Anstett V, Fahr N, Tanyi JL, Eiva MA, Jacobson CA, Montone KT, Westergaard MCW, Svane IM, Kandalaft LE, Delorenzi M, Sorger PK, Färkkilä A, Michielin O, Zoete V, Carmona SJ, Foukas PG, Powell DJ Jr, Rusakiewicz S, Doucey MA, Dangaj Laniti D, Coukos G. Duraiswamy J, et al. Among authors: kandalaft le. Cancer Cell. 2021 Dec 13;39(12):1623-1642.e20. doi: 10.1016/j.ccell.2021.10.008. Epub 2021 Nov 4. Cancer Cell. 2021. PMID: 34739845 Free PMC article.
Immune Therapy Opportunities in Ovarian Cancer.
Kandalaft LE, Odunsi K, Coukos G. Kandalaft LE, et al. Am Soc Clin Oncol Educ Book. 2020 May;40:1-13. doi: 10.1200/EDBK_280539. Am Soc Clin Oncol Educ Book. 2020. PMID: 32412818 Free article. Review.
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Gannon PO, Harari A, Auger A, Murgues C, Zangiacomi V, Rubin O, Ellefsen Lavoie K, Guillemot L, Navarro Rodrigo B, Nguyen-Ngoc T, Rusakiewicz S, Rossier L, Boudousquié C, Baumgaertner P, Zimmermann S, Trueb L, Iancu EM, Sempoux C, Demartines N, Coukos G, Kandalaft LE. Gannon PO, et al. Among authors: kandalaft le. Cytotherapy. 2020 Dec;22(12):780-791. doi: 10.1016/j.jcyt.2020.07.011. Epub 2020 Oct 14. Cytotherapy. 2020. PMID: 33069566
Immunotherapy in Ovarian Cancer: Are We There Yet?
Kandalaft LE, Odunsi K, Coukos G. Kandalaft LE, et al. J Clin Oncol. 2019 Sep 20;37(27):2460-2471. doi: 10.1200/JCO.19.00508. Epub 2019 Aug 12. J Clin Oncol. 2019. PMID: 31403857 Review. No abstract available.
94 results